112 related articles for article (PubMed ID: 12684687)
21. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Daoud SS; Munson PJ; Reinhold W; Young L; Prabhu VV; Yu Q; LaRose J; Kohn KW; Weinstein JN; Pommier Y
Cancer Res; 2003 Jun; 63(11):2782-93. PubMed ID: 12782583
[TBL] [Abstract][Full Text] [Related]
22. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
23. A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway.
Aglipay JA; Lee SW; Okada S; Fujiuchi N; Ohtsuka T; Kwak JC; Wang Y; Johnstone RW; Deng C; Qin J; Ouchi T
Oncogene; 2003 Dec; 22(55):8931-8. PubMed ID: 14654789
[TBL] [Abstract][Full Text] [Related]
24. Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis.
Dizin E; Ray H; Suau F; Voeltzel T; Dalla Venezia N
Apoptosis; 2008 Feb; 13(2):237-46. PubMed ID: 18071904
[TBL] [Abstract][Full Text] [Related]
25. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
[TBL] [Abstract][Full Text] [Related]
26. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.
Vernole P; Tedeschi B; Tentori L; Levati L; Argentin G; Cicchetti R; Forini O; Graziani G; D'Atri S
Mutat Res; 2006 Feb; 594(1-2):63-77. PubMed ID: 16139849
[TBL] [Abstract][Full Text] [Related]
27. Selenium protection from DNA damage involves a Ref1/p53/Brca1 protein complex.
Fischer JL; Lancia JK; Mathur A; Smith ML
Anticancer Res; 2006; 26(2A):899-904. PubMed ID: 16619485
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis in UV-C light irradiated p53 wild-type, apaf-1 and p53 knockout mouse embryonic fibroblasts: interplay of receptor and mitochondrial pathway.
Tomicic MT; Christmann M; Kaina B
Apoptosis; 2005 Dec; 10(6):1295-304. PubMed ID: 16215690
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
[TBL] [Abstract][Full Text] [Related]
30. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
Xing D; Orsulic S
Cancer Res; 2006 Sep; 66(18):8949-53. PubMed ID: 16982732
[TBL] [Abstract][Full Text] [Related]
31. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
Zuco V; Zanchi C; Cassinelli G; Lanzi C; Supino R; Pisano C; Zanier R; Giordano V; Garattini E; Zunino F
Cell Death Differ; 2004 Mar; 11(3):280-9. PubMed ID: 14657960
[TBL] [Abstract][Full Text] [Related]
32. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Kim MS; Blake M; Baek JH; Kohlhagen G; Pommier Y; Carrier F
Cancer Res; 2003 Nov; 63(21):7291-300. PubMed ID: 14612526
[TBL] [Abstract][Full Text] [Related]
34. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Liu X; Holstege H; van der Gulden H; Treur-Mulder M; Zevenhoven J; Velds A; Kerkhoven RM; van Vliet MH; Wessels LF; Peterse JL; Berns A; Jonkers J
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12111-6. PubMed ID: 17626182
[TBL] [Abstract][Full Text] [Related]
35. Selective protection of non-cancer cells by hypothermia.
Matijasevic Z
Anticancer Res; 2002; 22(6A):3267-72. PubMed ID: 12530074
[TBL] [Abstract][Full Text] [Related]
36. Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice.
Bachelier R; Xu X; Wang X; Li W; Naramura M; Gu H; Deng CX
Oncogene; 2003 Jan; 22(4):528-37. PubMed ID: 12555066
[TBL] [Abstract][Full Text] [Related]
37. Absence of p53 enhances growth defects and etoposide sensitivity of human cells lacking the Bloom syndrome helicase BLM.
So S; Adachi N; Koyama H
DNA Cell Biol; 2007 Jul; 26(7):517-25. PubMed ID: 17630856
[TBL] [Abstract][Full Text] [Related]
38. Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice.
Cressman VL; Backlund DC; Avrutskaya AV; Leadon SA; Godfrey V; Koller BH
Mol Cell Biol; 1999 Oct; 19(10):7061-75. PubMed ID: 10490643
[TBL] [Abstract][Full Text] [Related]
39. A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage.
Hohenstein P; Kielman MF; Breukel C; Bennett LM; Wiseman R; Krimpenfort P; Cornelisse C; van Ommen GJ; Devilee P; Fodde R
Oncogene; 2001 May; 20(20):2544-50. PubMed ID: 11420664
[TBL] [Abstract][Full Text] [Related]
40. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.
Bartz SR; Zhang Z; Burchard J; Imakura M; Martin M; Palmieri A; Needham R; Guo J; Gordon M; Chung N; Warrener P; Jackson AL; Carleton M; Oatley M; Locco L; Santini F; Smith T; Kunapuli P; Ferrer M; Strulovici B; Friend SH; Linsley PS
Mol Cell Biol; 2006 Dec; 26(24):9377-86. PubMed ID: 17000754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
